Inequalities in Survival from Cancer

Tomatis, Lorenzo

doi:10.1177/030089169708300113

Cited by 10 publications

(5 citation statements)

References 11 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Most of the wide global range in cancer survival is probably attributable to inequity in access to optimum diagnostic and treatment services, 6 both in rich 124–126 and poor 127,128 countries. Availability of linear accelerators varies more than ten-fold worldwide, from one machine per 500 000 population to less than one per five million people, and more than 30 countries in Africa and Asia have no radiotherapy service at all.…”

Section: Discussionmentioning

confidence: 99%

Global surveillance of cancer survival 1995–2009: analysis of individual data for 25 676 887 patients from 279 population-based registries in 67 countries (CONCORD-2)

et al. 2015

View full text Add to dashboard Cite

Summary Background Worldwide data for cancer survival are scarce. We aimed to initiate worldwide surveillance of cancer survival by central analysis of population-based registry data, as a metric of the effectiveness of health systems, and to inform global policy on cancer control. Methods Individual tumour records were submitted by 279 population-based cancer registries in 67 countries for 25·7 million adults (age 15–99 years) and 75 000 children (age 0–14 years) diagnosed with cancer during 1995–2009 and followed up to Dec 31, 2009, or later. We looked at cancers of the stomach, colon, rectum, liver, lung, breast (women), cervix, ovary, and prostate in adults, and adult and childhood leukaemia. Standardised quality control procedures were applied; errors were corrected by the registry concerned. We estimated 5-year net survival, adjusted for background mortality in every country or region by age (single year), sex, and calendar year, and by race or ethnic origin in some countries. Estimates were age-standardised with the International Cancer Survival Standard weights. Findings 5-year survival from colon, rectal, and breast cancers has increased steadily in most developed countries. For patients diagnosed during 2005–09, survival for colon and rectal cancer reached 60% or more in 22 countries around the world; for breast cancer, 5-year survival rose to 85% or higher in 17 countries worldwide. Liver and lung cancer remain lethal in all nations: for both cancers, 5-year survival is below 20% everywhere in Europe, in the range 15–19% in North America, and as low as 7–9% in Mongolia and Thailand. Striking rises in 5-year survival from prostate cancer have occurred in many countries: survival rose by 10–20% between 1995–99 and 2005–09 in 22 countries in South America, Asia, and Europe, but survival still varies widely around the world, from less than 60% in Bulgaria and Thailand to 95% or more in Brazil, Puerto Rico, and the USA. For cervical cancer, national estimates of 5-year survival range from less than 50% to more than 70%; regional variations are much wider, and improvements between 1995–99 and 2005–09 have generally been slight. For women diagnosed with ovarian cancer in 2005–09, 5-year survival was 40% or higher only in Ecuador, the USA, and 17 countries in Asia and Europe. 5-year survival for stomach cancer in 2005–09 was high (54–58%) in Japan and South Korea, compared with less than 40% in other countries. By contrast, 5-year survival from adult leukaemia in Japan and South Korea (18–23%) is lower than in most other countries. 5-year survival from childhood acute lymphoblastic leukaemia is less than 60% in several countries, but as high as 90% in Canada and four European countries, which suggests major deficiencies in the management of a largely curable disease. Interpretation International comparison of survival trends reveals very wide differences that are likely to be attributable to differences in access to early diagnosis and optimum treatment. Continuous worldwide surveillance of cancer surv...

show abstract

Section: Discussionmentioning

confidence: 99%

Global surveillance of cancer survival 1995–2009: analysis of individual data for 25 676 887 patients from 279 population-based registries in 67 countries (CONCORD-2)

et al. 2015

View full text Add to dashboard Cite

show abstract

“…It is evident that the slowness of the HCV‐triggered neoplastic induction process causes the cancer to be latent for many years (5). In the South of Italy, conditions are present which lead to a high prevalence of HCV (46–49): up to recent times there was extensive use of glass syringes, general poverty, poor education and sexual promiscuity (50, 51); besides, although the mean lifespan is long (75 years for men and 81 years for women), health procedures (surgical and dental interventions) and the health system in general are less efficient and less meticulous than in the rest of Italy (52, 53) and these phenomena also determine a lower survival for cancer patients in the South of Italy (54, 55). Our study, therefore, is particularly important for public health since it shows that in the South of Italy, because of the high prevalence of HCV and the long life expectancy, there are good reasons to expect increases in the numbers of cases of liver cancer, of tumors associated with the immune system and of thyroid cancer in years to come.…”

Section: Discussionmentioning

confidence: 99%

HCV and cancer: a case‐control study in a high‐endemic area

Montella¹,

Crispo²,

Bellis³

et al. 2001

Liver

View full text Add to dashboard Cite

show abstract

“…Health outcomes and care arrangements relating to medical treatment can also vary according to distance from major cities (Australian Institute of Health and Welfare, 2012; Kogevinas and Porta, 1997;Tomatis, 1997).…”

Section: Modelmentioning

confidence: 99%

Labour force participation of families coping with a disabling condition

Vecchio

2015

Economic Analysis and Policy

View full text Add to dashboard Cite

Inequalities in Survival from Cancer

Cited by 10 publications

References 11 publications

Global surveillance of cancer survival 1995–2009: analysis of individual data for 25 676 887 patients from 279 population-based registries in 67 countries (CONCORD-2)

Global surveillance of cancer survival 1995–2009: analysis of individual data for 25 676 887 patients from 279 population-based registries in 67 countries (CONCORD-2)

HCV and cancer: a case‐control study in a high‐endemic area

Labour force participation of families coping with a disabling condition

Contact Info

Product

Resources

About